RxDoctor Payments Data

Joel Franco, MD

Otolaryngology · Las Vegas, NVNPI 1891108452

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $295, 3.0 times the $100 reported in 2019. That places this record below the midpoint for otolaryngology clinicians in NV, where the typical reported total is $1,885.

$903in general payments, 2019–2025

Across 45 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$194
  • Optinose US, Inc.$193
  • Medtronic$100
  • Novo Nordisk$86
  • Regeneron Healthcare Solutions, Inc.$84
  • Sanofi$82
  • plus $166 from 6 others

What the payments were for

  • Food & beverage$903100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$903 in reported general payments places this provider in the 30th percentile of 41 otolaryngology providers in Nevada.

See all otolaryngology providers in Nevada

Medicare billing

Part B allowed, 2024
$119,899
Medicare patients
433
Services billed
1,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate20$15,756
Azelastine Hcl142$3,582
Ipratropium Bromide127$3,171
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth25$2,982
Fluticasone Propionate200$2,520
Mupirocin248$1,977
Doxycycline Hyclate74$657
Omeprazole70$504
Ciprofloxacin Hcl20$337
Dexamethasone14$231
Prednisone84$165
Nystatin13$157
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$111
Clindamycin Hcl16$106
Oxycodone Hcl26$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$193$15,75620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 41 otolaryngology providers in Nevada.

Other otolaryngology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →